Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73594541" target="_blank" >RIV/61989592:15110/19:73594541 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/20:10412245 RIV/65269705:_____/20:00072655 RIV/00179906:_____/20:10412245 RIV/00216224:14110/20:00118595

Result on the web

<a href="http://www.haematologica.org/content/early/2019/04/15/haematol.2018.208678.full.pdf+html" target="_blank" >http://www.haematologica.org/content/early/2019/04/15/haematol.2018.208678.full.pdf+html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2018.208678" target="_blank" >10.3324/haematol.2018.208678</a>

Result language

angličtina

Original language name

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study

Original language description

Acute myeloid leukemia with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of acute myeloid leukemia cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal with intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation may improve survival if applied early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 (range: 16-76) years, acute myeloid leukemia was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow-up of 5.43 years, estimated overall survival at 5 years was 38% (95%-CI, 31-47%). Allogeneic hematopoietic cell transplantation was performed in 117 (66%) patients, including 89 in first complete remission. Allogeneic hematopoietic cell transplantation in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy (45% [95%-CI, 35-59%] and 53% [95%-CI, 42-66%], vs. 7% [95%-CI, 3-19%] and 23% [95%-CI, 13-38%]. For patients undergoing allogeneic hematopoietic cell transplantation, overall survival rates at 5 years did not differ whether performed in first (53% [95%-CI, 42-66%]), or second complete remission (58% [95%-CI, 31-100%]; n=10) or with active disease/relapse (54% [95%-CI, 34-84%]; n=18) (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) acute myeloid leukemias are poor with chemotherapy, and can be substantially improved with allogeneic hematopoietic cell transplantation.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

<a href="/en/project/NV15-25809A" target="_blank" >NV15-25809A: National study of leukemia cell mutations and clonality in patients diagnosed with acute myeloid leukemia</a><br>

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

HAEMATOLOGICA

ISSN

0390-6078

e-ISSN

—

Volume of the periodical

105

Issue of the periodical within the volume

1

Country of publishing house

IT - ITALY

Number of pages

9

Pages from-to

161-169

UT code for WoS article

000505041200031

EID of the result in the Scopus database

2-s2.0-85077402825